Pure Biologics (STU:PQB) Total Liabilities: €4.16 Mil (As of Mar. 2026)


STU:PQB Pure Biologics SA STU:PQB
19 GF Score
Price €0.40
! 2 Warning Signs
View Full Analysis

What is Pure Biologics Total Liabilities?

Pure Biologics STU:PQB -1.94% 19 Total Liabilities is €4.16 Mil as of Mar. 2026. GuruFocus rates STU:PQB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Pure Biologics's Total Liabilities for the quarter that ended in Mar. 2026 was €4.16 Mil.

Pure Biologics's quarterly Total Liabilities declined from Sep. 2025 (€4.79 Mil) to Dec. 2025 (€4.42 Mil) and declined from Dec. 2025 (€4.42 Mil) to Mar. 2026 (€4.16 Mil).

Pure Biologics's annual Total Liabilities declined from Dec. 2023 (€4.82 Mil) to Dec. 2024 (€3.58 Mil) but then increased from Dec. 2024 (€3.58 Mil) to Dec. 2025 (€4.42 Mil).

Pure Biologics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pure Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics Total Liabilities Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 3.41 4.82 3.58 4.42

Pure Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.65 4.64 4.79 4.42 4.16
STU:PQB
19GF Score
Pure Biologics SA STU:PQB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pure Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pure Biologics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.387+(0.03+2.4980018054066E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.42

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.143--3.274
=4.42

Pure Biologics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.161+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.16

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=0.368--3.793
=4.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €4.16 Mil mean?
Pure Biologics (STU:PQB) has a Total Liabilities of €4.16 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pure Biologics and its competitors.
Is Pure Biologics' Total Liabilities too high?
Pure Biologics' current Total Liabilities is €4.16 Mil. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Total Liabilities compare to VRTX and REGN?
Pure Biologics' Total Liabilities of €4.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pure Biologics and its competitors. Pure Biologics's current Total Liabilities is €4.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current Total Liabilities of €4.16 Mil. The current Total Liabilities is €4.16 Mil. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current Total Liabilities is €4.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Other Exchanges PUR:Poland
Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score

Get the complete analysis for STU:PQB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price